Anticancer Methods Employing Extracts of Gleditsia sinensis Lam

• US 20120045532A1
• Filed: 11/01/2011
• Published: 02/23/2012
• Est. Priority Date: 04/11/2008
• Status: Abandoned Application

• Current Assignee: Bionovo, Inc.
• Original Assignee: Bionovo, Inc.
• Inventors: Cohen, Isaac
• Application Number:
  US13/286,883
• Publication Number:
  US 20120045532A1
• Time in Patent Office: Days
• US Class Current: 424/769
• CPC Class Codes: A61K 36/483 Gleditsia (locust)
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Selective apoptotic extracts of Gleditsia sinensis Lam are provided. Also provided are methods of using said extracts to induce apoptosis in specific cells, especially in a human. Provided as well are uses of the extracts of Gleditsia sinensis Lam for the preparation of a medicament for the selective induction of apoptosis.

Claims

1. A method of treating a patient having estrogen receptor (ER) negative breast cancer, comprising administering to the patient a therapeutically effective amount of an agent selected from the group consisting of an extract of Gleditsia sinensis Lam, oleanolic acid, a pharmaceutically acceptable salt of oleanolic acid, and a combination of two or more thereof.

2. The method of claim 1, wherein the therapeutically effective amount of the agent is about 0.001 to about 100 grams dry weight of the agent per day.

3. The method of claim 1, wherein the ER negative breast cancer is also negative for one or both of progesterone receptor (PR) and/or Her2/neu.

4. The method of claim 1, wherein the ER negative breast cancer is triple negative breast cancer.

5. The method of claim 1, wherein the ER negative breast cancer is metastatic.

6. The method of claim 1, wherein the agent is in an oral dosage form.

7. A pharmaceutical composition comprising a therapeutically effective amount of an agent selected from the group consisting of an extract of Gleditsia sinensis Lam, oleanolic acid, a pharmaceutically acceptable salt of oleanolic acid, and combinations of two or more thereof, wherein the therapeutically effective amount is an amount effective to treat estrogen receptor (ER) negative breast cancer.

8. The pharmaceutical composition of claim 7, wherein the therapeutically effective amount of the agent is about 0.001 to about 100 grams dry weight of the agent per day.

9. The pharmaceutical composition of claim 7, wherein the ER negative breast cancer is also negative for one or both of progesterone receptor (PR) and/or Her2/neu.

10. The pharmaceutical composition of claim 7, wherein the ER negative cancer is triple negative breast cancer.

11. The pharmaceutical composition of claim 7, wherein the cancer is metastatic.

12. The pharmaceutical composition of claim 7, wherein the extract of Gleditsia sinensis Lam is in an oral dosage form.

13. A method of treating a patient having cancer that does not express an estrogen receptor (ER), comprising administering a therapeutically effective amount of an agent selected from the group consisting of an extract of Gleditsia sinensis Lam, oleanolic acid, a pharmaceutically acceptable salt of oleanolic acid, and combinations of two or more thereof.

14. The method of claim 13, wherein the therapeutically effective amount of the agent is about 0.001 to about 100 grams dry weight of the agent per day.

15. The method of claim 13, wherein the agent is in an oral dosage form.

16. The method of claim 13, wherein the cancer that does not express the ER is selected from the group consisting of:

bone cancer, brain stem glioma, breast cancer, cancer of the adrenal gland, cancer of the anal region, cancer of the bladder, cancer of the endocrine system, cancer of the esophagus, cancer of the head or neck, cancer of the kidney, cancer of the ureter, cancer of the parathyroid gland, cancer of the penis, cancer of the small intestine, cancer of the thyroid gland, cancer of the urethra, carcinoma of the cervix, carcinoma of the endometrium, carcinoma of the fallopian tubes, carcinoma of the renal pelvis, carcinoma of the vagina, carcinoma of the vulva, chronic or acute leukemia, colon cancer, cutaneous or intraocular melanoma, glioma, Hodgkin'"'"'s Disease, lung cancer, lymphocytic lymphomas, neoplasms of the central nervous system (CNS), ovarian cancer, pancreatic cancer, pituitary adenoma, primary CNS lymphoma, prostate cancer, rectal cancer, renal cell carcinoma, a sarcoma, a skin cancer, spinal axis tumors, stomach cancer, uterine cancer, and combinations thereof.

17. A pharmaceutical composition comprising a therapeutically effective amount of an agent selected from the group consisting of an extract of Gleditsia sinensis Lam, oleanolic acid, or a pharmaceutically acceptable salt of oleanolic acid, wherein the therapeutically effective amount of the agent is an about that is effective to treat a cancer that does not express an estrogen receptor (ER).

18. The pharmaceutical composition of claim 17, wherein the therapeutically effective amount of the agent is about 0.001 to about 100 grams dry weight of the agent per day.

19. The pharmaceutical composition of claim 17, wherein the agent is in an oral dosage form.

20. The pharmaceutical composition of claim 17, wherein the cancer that does not express the ER is selected from the group consisting of:

bone cancer, brain stem glioma, breast cancer, cancer of the adrenal gland, cancer of the anal region, cancer of the bladder, cancer of the endocrine system, cancer of the esophagus, cancer of the head or neck, cancer of the kidney, cancer of the ureter, cancer of the parathyroid gland, cancer of the penis, cancer of the small intestine, cancer of the thyroid gland, cancer of the urethra, carcinoma of the cervix, carcinoma of the endometrium, carcinoma of the fallopian tubes, carcinoma of the renal pelvis, carcinoma of the vagina, carcinoma of the vulva, chronic or acute leukemia, colon cancer, cutaneous or intraocular melanoma, glioma, Hodgkin'"'"'s Disease, lung cancer, lymphocytic lymphomas, neoplasms of the central nervous system (CNS), ovarian cancer, pancreatic cancer, pituitary adenoma, primary CNS lymphoma, prostate cancer, rectal cancer, renal cell carcinoma, a sarcoma, a skin cancer, spinal axis tumors, stomach cancer, uterine cancer, and combinations thereof.

21. A method of treating a patient having estrogen receptor (ER) negative breast cancer, comprising administering a therapeutically effective amount of at least one saponin, or a pharmaceutically acceptable salt thereof, to the patient, wherein the saponin possesses mTORC1, mTORC2, and/or possesses Akt inhibitory activity, and/or disrupts lipid rafts (LRs) in vitro.

22. The method of claim 21, wherein the saponin possesses mTORC1 and mTORC2 activity, the saponin possesses Akt inhibitory activity, and the saponin disrupts lipid rafts.

23. The method of claim 21, wherein the therapeutically effective amount of the saponin is about 0.001 to about 100 grams dry weight per day.

24. A pharmaceutical composition comprising a therapeutically effective amount of at least one saponin, or a pharmaceutically acceptable salt thereof, wherein the saponin possesses mTORC1, mTORC2, and/or possesses Akt inhibitory activity, and/or disrupts lipid rafts (LRs) in vitro.

25. The pharmaceutical composition of claim 24, wherein the saponin possesses mTORC1 and mTORC2, the saponin possesses Akt inhibitory activity, and the saponin disrupts lipid rafts.

26. The pharmaceutical composition of claim 24, wherein the therapeutically effective amount of the saponin is about 0.001 to about 100 grams dry weight of the saponin per day.

27. A method of treating a patient having cancer that does not express an estrogen receptor (ER), comprising administering a therapeutically effective amount of a saponin to the patient, wherein the saponin possesses mTORC1, mTORC2, and/or possesses Akt inhibitory activity, and/or disrupts lipid rafts (LRs) in vitro.

28. The method of claim 27, wherein the saponin possesses mTORC1 and mTORC2 activity, the saponin possesses Akt inhibitory activity, and the saponin disrupts lipid rafts.

29. The method of claim 27, wherein the therapeutically effective amount of the saponin is about 0.001 to about 100 grams dry weight of the saponin per day.

30. The method of claim 27, wherein the saponin, or pharmaceutically acceptable salt or derivative thereof, is in an oral dosage form.